About diarobo

Mission

Diastolic Robotics' mission is to improve patient care. We want to:

  • Make tough procedures and cases easier.
  • Eliminate unnecessary delay and injury.
  • Save time, money and resources, and - of course - lives.

To these ends Diastolic Robotics Incorporated (DRI) works in medicine and engineering, developing drug and device solutions.

History

Drawing of THASA (Tissue and Heart Stabilization Tool) mounted to chest retractor.

Diastolic Robotics™ — also known as diarobo™ — was started to commercialize products in the surgical robotics space, specifically surgical tools for heart stabilization during coronary artery bypass procedures. One such device was THASA, the Tissue and Heart Stabilization Tool, which is described in United States patent:

6,210,323 Surgical arm and tissue stabilizer

THASA held sections of the heart still for coronary artery bypass grafting procedures, allowing work to progress off-pump.

Following THASA, DRI expanded into medical device consulting and software development. Some of the software projects included simulation and modelling programs:

  • Drugflow Simulation: Software for the simulation of drug flow in a theoretical patient.
  • Pharmacokinetic modelling: Modelling of concentration-time data.
Obstructive Sleep Apnea Screener Tests screen

Currently DRI's software projects include apps and other software for medical professionals. These projects include:

  • Obstructive Sleep Apnea Screener (OSAS):   a tool to assist anesthesiologists and other healthcare staff to determine the likelihood of a patient suffering from sleep apnea. This tool amalgamates several sleep apnea screening checklists and makes them available to the health professional in a mobile format.

More recently, DRI has been commercializing products for individualizing drug therapies, specifically neuromuscular blockers (NMB) but with many other indications in mind, and other projects in anesthesia. NMB drugs are safe, but subject to frequent incidences of under- and overdosing due to dose-by-weight regimens. We have a solution that reduces these incidences, as we demonstrated in a 60 patient clinical trial. Please view the NMB Projects page for the details.

DRI has also been working on other anesthesia products and projects. Please see the Products for Anesthesia page for the details.